Alix Ventures Research
Overview
Alix Ventures is a thesis-driven, early-stage venture capital fund focused exclusively on TechBio—companies that merge technology and biology to drive transformative patient impact. Founded by healthcare entrepreneurs and venture capitalists with deep operational experience, Alix combines capital deployment with an extensive support ecosystem including a 1000+ member BIOS community, scientific advisory board of PhD founders, and operational expertise from veteran healthcare executives.
Investment Thesis & Philosophy
Core Thesis: Life sciences is experiencing unprecedented innovation through the rise of TechBio—companies that engineer biology using computational tools, automation, and computational infrastructure. This convergence is generating some of the most impactful healthcare solutions in decades. Alix believes the best opportunities lie in supporting passionate, accomplished founders with unique insights to solve daring problems in life sciences and significantly impact patient care.
Mission Statement: "Driving Patient Impact" through partnerships with visionary founders building transformative biotechnology companies that advance human health.
Unique Positioning: Unlike traditional biotech VCs, Alix operates as a venture studio ecosystem. The fund doesn't just provide capital—it actively builds a community, offers operational support, facilitates industry relationships, and leverages a scientific advisory board of bioengineering PhD founders to guide portfolio companies through technical challenges.
Investment Focus & Sectors
Alix Ventures maintains a focused mandate on TechBio and life sciences infrastructure across several core domains:
Primary Focus Areas:
- Drug Development Infrastructure: Platforms enabling faster, more efficient drug discovery and development (e.g., synthesis platforms, manufacturing optimization)
- Tech-Enabled Therapeutics Platforms: Companies applying engineering biology and computation to develop novel treatments
- Tech-Enabled Diagnostics Platforms: Diagnostic tools leveraging AI, computation, and biotechnology
- Genomic Data Platforms: Infrastructure for genomic analysis, interpretation, and data management
- Gene Editing & Synthetic Biology: CRISPR alternatives, gene delivery, gene therapy platforms, strand therapeutics
- Clinical Trial Platforms: Technology enabling faster, more efficient clinical trials
- Lab Automation & Robotics: Automation infrastructure for life science research and manufacturing
- Cell & Gene Therapy Manufacturing: Infrastructure and manufacturing platforms for CGT and cell therapy
- Single-Cell Screening & Analysis: Technologies enabling high-throughput screening and profiling
Current Portfolio Focus (18+ investments across stages):
- Xilis (precision medicine via patient-derived micro-organoids)
- Elegen (full-stack DNA writing)
- 64x (viral vector manufacturing)
- Mythic (therapeutic potency enhancement)
- Endpoint Health (precision immunology)
- Zafrens (single-cell screening)
- Teiko (immune system profiling)
- Strand (logic-gated gene therapy)
- Exthymic (cell therapy manufacturing)
- STRM (non-viral gene delivery)
- Chemify (chemical synthesis automation)
- Cytosolix (tumor acidity targeting)
Stage Focus & Check Size
Stage Preference:
- Primary: Pre-seed and Seed ($250K-$500K initial tickets)
- Secondary: Series A (selective follow-ons and co-investments)
- Venture Studio Model: Incubates companies from concept
Check Size:
- Current range: $100K - $500K (per API data showing min=$100K, max=$500K)
- Typical deployment: $250K-$350K for seed stage companies
- Active follow-on reserves for portfolio companies
- Mark Pulido (Operating Partner, 5x CEO) provides strategic operational support
Portfolio Performance:
- 700+ jobs created across portfolio
- $850M+ total capital raised by portfolio companies
- $2.5B+ collective value created
- 25% female-founded companies
- 40% diversity representation
- 60% solo-founded companies
Lead Tendency & Decision Process
Lead Tendency: Both (Leads and Co-Leads)
Alix actively leads seed rounds while also participating in syndicated rounds with complementary co-investors. The firm's strong operational support and scientific expertise make them attractive co-investors for larger rounds.
Decision Process: Partnership Model
The investment team is structured around partnerships and scientific expertise:
- Chas Pulido - Founder & General Partner (3rd generation healthcare CEO, serial entrepreneur, venture capitalist)
- Nick Goldner - Venture Partner (CEO Founder, WashU PhD scientist)
- Mark Pulido - Operating Partner (5x CEO with deep healthcare industry experience)
- Scientific Advisory Board - Brian Fiske (Mythic co-founder, MIT PhD), Daniel Delubac (Startup exec at Counsyl/Guardant), Jake Becraft (Strand Therapeutics co-founder/CEO, MIT PhD)
Decision Timeline: 2-3 weeks (typical for seed-stage VCs)
The partnership model and deep scientific expertise enable quick evaluation of technical feasibility and commercial potential.
Recent Activity & Fund Status
Fund Status: Actively Deploying
Alix continues consistent deployment from current fund with recent activities spanning 2025-2026.
Recent Notable Activity:
- October 2025: Investment in iOrganBio (organoid technology)
- Ongoing deployment across pre-seed and seed stages
- Strong follow-on support for portfolio companies advancing to Series A
- Active ecosystem building through BIOS community (1000+ members)
Portfolio Milestone Companies:
- Endpoint Health - Secured oversubscribed $52M Series A with active support from Alix
- Zafrens - Co-founder Kayj Shannon now part of Alix's Venture Residency program
- Multiple exits - Circularis acquired by Gingko Bioworks
Investment Team & Leadership
Chas Pulido, Founder & General Partner
- 3rd generation healthcare CEO with serial entrepreneurship background
- Venture capital experience building the fund
- Mission-driven focus on patient impact
- Sourcing and deal evaluation
Nick Goldner, Venture Partner
- CEO Founder background
- WashU PhD scientist (deep technical expertise)
- Building TechBio future
- Scientific evaluation and due diligence
Mark Pulido, Operating Partner
- 5-time CEO with 40+ years of leadership experience
- Healthcare IT, Health Services, Big Pharma, Diagnostics background
- Private Equity and Venture-backed startup experience
- Direct portfolio and fund support
Scientific Advisory Board:
- Brian Fiske (Co-Founder/CSO Mythic, MIT PhD) - Drug Development expertise
- Daniel Delubac (Startup exec Counsyl/Guardant/Freenome/Xilis, CMU PhD) - Diagnostics/Lab Services
- Jake Becraft (Co-Founder/CEO Strand Therapeutics, MIT PhD) - Synthetic Biology/Cell & Gene Therapy
Founder Preferences
Alix seeks founders who embody:
- Visionary & Passionate: "Passionate accomplished founders with unique insights" - driven to solve daring life science problems
- Technical Expertise: PhDs, bioengineers, MDs with deep domain knowledge
- Operational Capability: Demonstrated execution ability; preference for founders with prior startup or industry experience
- Founder Mentality: Understanding of the "this needs to be done yesterday" urgency in healthcare
- Coachability: Openness to partnership, operational guidance, and strategic input
- Diversity: Active recruitment of diverse founders (40% diversity representation in portfolio)
Summary
Alix Ventures is a specialized, thesis-driven early-stage VC fund focused exclusively on TechBio. Founded by healthcare entrepreneurs with deep operational experience, the firm combines disciplined capital deployment ($250K-$500K typical checks) with an extensive ecosystem of scientific advisory, operational support, and industry relationships. The 18+ portfolio companies (700+ jobs created, $2.5B+ value) reflect a focus on transformative technologies across drug development infrastructure, diagnostics, gene therapy, and cell manufacturing.
With active portfolio support evidenced by milestone exits (Endpoint Health's $52M Series A) and visible co-investor relationships, Alix Ventures has established itself as the premier early-stage TechBio partner for passionate founders seeking both capital and operational partnership to build world-changing companies.